Abstract Library

Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.

Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.

 

Please note:

Participants of the 2025 ENETS Conference enjoy full access to the 2025 conference digital resources through myENETS: the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more.

Log in to myENETS

ENETS Abstract Search

#3952 Peptide Receptor Radionuclide Therapy (PRRT) in the management of patients with ectopic Cushing’s syndrome due to metastatic gastroenteropancreatic neuroendocrine neoplasia (GEPNEN): A single centre experience

Introduction: Metastatic GEPNEN can cause ectopic Cushing’s syndrome (ECS). ECS is highly morbid and often refractory to medical therapy. Bilateral adrenalectomy (BA) carries risk and long-term morbidity. Patients (pts) unsuitable for surgery have dismal outcomes. Peptide receptor radionuclide therapy (PRRT) is a rational option for hormone control in ECS caused by NEN with high somatostatin receptor (SSTR) expression yet detailed case series to guide its use are lacking.

Conference:

Presenting Author: Boehm E

Authors: Boehm E, Hung T, Akhurst T, Alipour R, Cardin A,

Keywords: GEPNEN, PRRT, Ectopic Cushing's Syndrome,

#3470 Molecular Imaging Tumor Volume of Somatostatin Receptor (MITVSSR) on 68Ga-DOTATATE PET/CT, dosimetry and predictors of overall survival and response in unresectable neuroendocrine neoplasms treated with Peptide Receptor Radionuclide Therapy (PRRT)

Introduction: PRRT delivers targeted radionuclide therapy to Neuroendocrine Neoplasms (NENs) with high SSR expression.

Conference:

Presenting Author:

Authors: Alipour R, Jackson P, Callahan J, Bressel M, Hogg A,

Keywords: PRRT, dosimetry, survival, response,

#3176 Tissue sample collection from patients with neuroendocrine tumor (NET) treated with peptide receptor radionuclide therapy (PRRT) for future blood disease research

Introduction: Peptide receptor radionuclide therapy (PRRT) is an effective treatment for patients with metastatic NET. However, the development of therapy-related myeloid neoplasms (t-MN) is an infrequent but serious complication. T-MN after PRRT occurs at higher frequency compared to other solid tumor chemotherapies and harbour unfavourable genetic mutations with poor treatment outcomes. Prospective data is needed to explore pre-existing genetic factors and predictive biomarkers to minimise t-MN risk.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Kong G

Authors: Kong G, Michael M, Alipour R, Akhurst T, Hicks R,

Keywords: t-MN, PRRT, PRCRT, marrow biopsy,